In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAF V600E in melanoma

Snowball: resampling combined with distance-based regression to discover transcriptional consequences of a driver mutation

(2014) Yaomin Xu et al.   BIOINFORMATICS

Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays

(2014) Martin J. Aryee et al.   BIOINFORMATICS

IL-1β Upregulates IL-8 Production in Human Müller Cells Through Activation of the p38 MAPK and ERK1/2 Signaling Pathways

(2014) Xiufen Liu et al.   INFLAMMATION

A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance

(2014) J. Xia et al.   MOLECULAR CANCER THERAPEUTICS

Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis

(2014) T. J. Parmenter et al.   Cancer Discovery

A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

(2014) D. J. Konieczkowski et al.   Cancer Discovery

Directed Phenotype Switching as an Effective Antimelanoma Strategy

(2013) Magalí Sáez-Ayala et al.   CANCER CELL

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

(2013) Cory M. Johannessen et al.   NATURE

Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma

(2013) J. J. Gartner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BCL2A1is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition

(2013) Rizwan Haq et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

(2013) E. M. Van Allen et al.   Cancer Discovery

Cancer Epigenetics: From Mechanism to Therapy

(2012) Mark A. Dawson et al.   CELL

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

The BRAFV600E causes widespread alterations in gene methylation in the genome of melanoma cells

(2012) Peng Hou et al.   CELL CYCLE

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

(2012) J. S. Khalili et al.   CLINICAL CANCER RESEARCH

Cancer epigenomics: beyond genomics

(2012) Juan Sandoval et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

BRAFV600Eremodels the melanocyte transcriptome and inducesBANCRto regulate melanoma cell migration

(2012) Ross J. Flockhart et al.   GENOME RESEARCH

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET ONCOLOGY

Epidermal growth factor (EGF) and interleukin (IL)-1β synergistically promote ERK1/2-mediated invasive breast ductal cancer cell migration and invasion

(2012) Liqiang Ma et al.   Molecular Cancer

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials

(2012) Christine M. Lovly et al.   PLoS One

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma

(2011) T Strub et al.   ONCOGENE

TGF-β Regulates DNA Methyltransferase Expression in Prostate Cancer, Correlates with Aggressive Capabilities, and Predicts Disease Recurrence

(2011) Qiang Zhang et al.   PLoS One

Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer

(2011) H. W. Cheung et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Resistance to transforming growth factor  -mediated tumor suppression in melanoma: are multiple mechanisms in place?

(2010) A. Lasfar et al.   CARCINOGENESIS

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

(2010) Jill C Rubinstein et al.   Journal of Translational Medicine

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

(2009) M. D. Robinson et al.   BIOINFORMATICS

The Aryl Hydrocarbon Receptor Functions as a Tumor Suppressor of Liver Carcinogenesis

(2009) Y. Fan et al.   CANCER RESEARCH

Oncogenic BRAFV600EInduces Expression of Neuronal Differentiation Marker MAP2 in Melanoma Cells by Promoter Demethylation and Down-regulation of Transcription Repressor HES1

(2009) Nityanand Maddodi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cross-talk between Aryl Hydrocarbon Receptor and Mitogen-Activated Protein Kinase Signaling Pathway in Liver Cancer through c-raf Transcriptional Regulation

(2008) J. Borlak et al.   MOLECULAR CANCER RESEARCH

Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas

(2008) Caroline Kannengiesser et al.   Molecular Oncology

Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF

(2008) Claudia Wellbrock et al.   PLoS One